Pengfei Sun

No. 107, West Wenhua Road
Jinan, 250012, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Delivery of a ZBP1 agonist enhances radiotherapy-induced antitumour immunity in hepatocellular carcinoma.

Delivery of a ZBP1 agonist enhances radiotherapy-induced antitumour immunity in hepatocellular carcinoma.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: April 07, 2026

Multimodal Modeling Distinguishes Treatment Response from Overall Survival in Hepatocellular Carcinoma Receiving Combined Interventional and Targeted Immunotherapy.

Multimodal Modeling Distinguishes Treatment Response from Overall Survival in Hepatocellular Carcinoma Receiving Combined Interventional and Targeted Immunotherapy.

Journal: Journal of hepatocellular carcinoma

Published: March 30, 2026

The association between sarcopenia and the prognosis of patients with high tumor burden hepatocellular carcinoma receiving hepatic artery infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitor: a multicenter, propensity score matching comparative study.

The association between sarcopenia and the prognosis of patients with high tumor burden hepatocellular carcinoma receiving hepatic artery infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitor: a multicenter, propensity score matching comparative study.

Journal: Frontiers in immunology

Published: January 06, 2026

Integrated Radiation Therapy With Immune-Chemotherapy for Unresectable Biliary Tract Cancer: An Exploratory Pilot Study.

Integrated Radiation Therapy With Immune-Chemotherapy for Unresectable Biliary Tract Cancer: An Exploratory Pilot Study.

Journal: International journal of radiation oncology, biology, physics

Published: June 11, 2025

Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity score matching comparative study.

Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity score matching comparative study.

Journal: Hepatology international

Published: April 27, 2025

Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis.

Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis.

Journal: International journal of surgery (London, England)

Published: December 12, 2024

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial.

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial.

Journal: BMC cancer

Published: October 25, 2024

Hepatic Arterial Infusion Chemotherapy Enhances the Efficacy of Lenvatinib Plus PD-1 Inhibitors in Hepatocellular Carcinoma Patients with Tumor Thrombosis in the Inferior Vena Cava and/or Right Atrium.

Hepatic Arterial Infusion Chemotherapy Enhances the Efficacy of Lenvatinib Plus PD-1 Inhibitors in Hepatocellular Carcinoma Patients with Tumor Thrombosis in the Inferior Vena Cava and/or Right Atrium.

Journal: Academic radiology

Published: July 28, 2024

Clinical study on conversion therapy of hepatocellular carcinoma - summary and comparison of clinical data from a single center of consecutive four years.

Clinical study on conversion therapy of hepatocellular carcinoma - summary and comparison of clinical data from a single center of consecutive four years.

Journal: BMC gastroenterology

Published: June 27, 2024

Preclinical Evaluation and Pilot Clinical Study of CD137 PET Radiotracer for Noninvasive Monitoring Early Responses of Immunotherapy.

Preclinical Evaluation and Pilot Clinical Study of CD137 PET Radiotracer for Noninvasive Monitoring Early Responses of Immunotherapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: May 15, 2024

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.

Journal: BMC cancer

Published: March 03, 2024

Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study.

Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study.

Journal: Journal of cancer research and therapeutics

Published: November 01, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026